Sangamo Therapeutics, Inc. (FRA:GBY)

Market Cap	151.67M -32.0%
Revenue (ttm)	28.02M -37.1%
Net Income	-92.82M
EPS	-0.38
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	50
Average Volume	318
Open	0.3280
Previous Close	0.3035
Day's Range	0.3025 - 0.3280
52-Week Range	0.3025 - 1.1550
Beta	n/a
RSI	58.92
Earnings Date	Mar 19, 2026

About Sangamo Therapeutics

Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company’s clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of imm...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1995
• Employees: 183
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: GBY

Financial Performance

In 2024, Sangamo Therapeutics's revenue was $57.80 million, a decrease of -67.20% compared to the previous year's $176.23 million. Losses were -$97.94 million, -62.01% less than in 2023.

Financial numbers in USD